Mendeleev Commun., 2004, 14(4), 178-179

Mendeleev Communications

## Synthesis of silicon-substituted hydroxylapatite

Natalya V. Plokhikh,<sup>a</sup> Alexander V. Soin,<sup>a</sup> Alexander V. Kuznetsov,<sup>a</sup> Alexander G. Veresov,\*a Valery I. Putlayev<sup>b</sup> and Yuri D. Tretyakov<sup>a,b</sup>

<sup>a</sup> Department of Materials Science, M. V. Lomonosov Moscow State University, 119992 Moscow, Russian Federation. Fax: +7 095 939 0998; e-mail: veres@inorg.chem.msu.ru

DOI: 10.1070/MC2004v014n04ABEH001975

Silicon-substituted hydroxylapatite was prepared to produce a biomaterial with improved bioactivity via aliovalent anion substitution, which leads to the instability of apatite  $Ca_5(PO_4)_3OH$  at T > 900 °C and to the formation of a  $Ca_3(PO_4)_2$  phase.

Synthetic hydroxylapatite  $Ca_{10}(PO_4)_6(OH)_2$  (HA) is extensively used in modern medicine as a bone restorative material due to its close chemical similarity to the natural tissue. HA ceramics is almost inert in contact with living bone; the reason is a low solubility of hydroxylapatite  $(IP_{HA} \sim 10^{-119} \, \mathrm{M}^{18})$ .\frac{1}{10} Many researches are focused on the biphasic ceramics of HA and more soluble tricalcium phosphate  $Ca_3(PO_4)_2$  (TCP)  $(IP_{TCP} \sim 10^{-25} \, \mathrm{M}^5)$ . Another approach to improve the bioactivity of HA is to modify its chemical composition in order to make the composition closer to a carbonate-containing bone mineral.\frac{2-5}{2} Note that 'bioactivity' is a complex term including (a) the dissolution of a material in acidic media and (b) the formation of a new apatite layer on the surface of a material from supersaturated body fluids.

The clinical application of glass ceramics developed by Hench¹ in the CaO–Na<sub>2</sub>O–SiO<sub>2</sub>–P<sub>2</sub>O<sub>5</sub> system demonstrates a great advantage of the incorporation of silicon in a biomaterial. It is known that silanol (–SiOH) groups promote the nucleation of the new apatite layer on the surface of the material leading to fast bone bonding process. Several attempts have been made to synthesise the Si-incorporated hydroxylapatite (Si-HA),<sup>2–5</sup> but only Gibson *et al.*³ reported the formation of the thermally stable (with respect to decay into tricalcium phosphates – TCP and secondary phases) product. The purpose of this study was to synthesise Si-doped HA and to examine its high-temperature stability.

The Si-HA was prepared by a conventional precipitation technique using  $Ca(NO_3)_2$  and  $KH_2PO_4$  solutions (at 80 °C, 5 h). Amorphous calcium phosphate (ACP) formed at the first step was treated with tetraethyl orthosilicate (TEOS) solution:

$$\begin{aligned} &10\text{Ca}(\text{NO}_3)_2 + (6-2x)\text{KH}_2\text{PO}_4 + x\text{Si}(\text{OEt})_4 + x\text{K}_2\text{SO}_4 + 14\text{KOH} \Rightarrow & (1) \\ &\text{Ca}_{10}(\text{PO}_4)_{6-2x}\text{SiO}_4)_x(\text{SO}_4)_x(\text{OH})_2 + 20\text{KNO}_3 + 4x\text{EtOH} + (12-4x)\text{H}_2\text{O} \end{aligned}$$

A sulfate-containing component was used to balance the net charge in apatite structure through aliovalent anion substitution:

$$2PO_4^{3-} \leftrightarrow SiO_4^{4-} + SO_4^{2-} \tag{2}$$

Another set of experiments was performed with previously synthesised pure HA: the crystals were modified with TEOS on their surface (with or without  $K_2SO_4$ ):

$$\begin{array}{c} {\rm Ca_{10}(PO_4)_6(OH)_2 + xSiO_4^{4-} \Rightarrow} \\ {\rm Ca_{10}(PO_4)_{6-x}(SiO_4)_x(OH)_{2-x} + xOH^- + xPO_4^{3-}} \end{array} \eqno(3)$$

All as-prepared samples were thermally treated at 950–1300 °C to analyse the high-temperature stability of Si-doped HA. Specimens were analysed by powder X-ray diffraction [XRD; DRON-3M, 'Bourevestnik', USSR;  $\lambda(\text{CuK}\alpha) = 1.54183 \text{ Å}$ ],




Figure 1 XRD patterns of Si-HA samples after annealing at 1300 °C.

scanning (SEM; Supra 50 VP, Leo, Germany) and transmission (TEM; Jem-2000 FXII, Jeol, Japan) electron microscopy and IR spectroscopy (400–4000 cm<sup>-1</sup>, PE-1600 FTIR, Perkin–Elmer, USA).

It was found that hydrated silica inhibited the crystallization of HA. One could observe an increase in X-ray peaks width with increasing concentration of TEOS. High temperature treatment of the samples  $\text{Ca}_{10}(\text{PO}_4)_{6-2x}(\text{SiO}_4)_x(\text{SO}_4)_x(\text{OH})_2$  with x>0.25 prepared by reaction (1) at  $1300\,^{\circ}\text{C}$  led to HA decomposition and to the formation of  $\text{Ca}_3(\text{PO}_4)_2$  and CaO as secondary phases (Figure 1). Silicon was reported to stabilise the  $\alpha$ -TCP phase promoting the decomposition of HA.<sup>5</sup> The crystal structure of  $\alpha$ -TCP is related to HA unit cell, and the solubility of  $\text{Ca}_2\text{SiO}_4$  in  $\alpha$ -TCP is about 4 wt.% according to the known phase diagram.<sup>6</sup> To conclude, the solubility of calcium silicate in the HA structure cannot be much higher than the TCP limit.

An increase in HA unit cell (hexagonal  $P6_3/m$ ) parameters after silicon doping is consistent with the ionic radii of silicate and phosphate (bond length Si–O = 1.66 Å, P–O = 1.55 Å):

$$\begin{array}{c} {\rm Ca_{10}(PO_4)_6(OH)_2}, a=b=9.415(3) \; {\rm \AA}, \; c=6.877(2) \; {\rm \AA}; \\ {\rm Ca_{10}(PO_4)_{5.5}(SiO_4)_{0.25}(SO_4)_{0.25}(OH)_2}, \; a=b=9.439(4) \; {\rm \AA}, \\ c=6.899(3) \; {\rm \AA}. \end{array}$$

IR-spectroscopic data of HA and Si-HA samples revealed another mechanism of charge compensation: partial substitution

b Department of Chemistry, M. V. Lomonosov Moscow State University, 119992 Moscow, Russian Federation

of  $\mathrm{CO}_3^2$  for  $\mathrm{PO}_4^{3-}$  and formation of  $\mathrm{Ca}_{10}(\mathrm{PO}_4)_{6-2x}(\mathrm{SiO}_4)_x$ - $(\mathrm{CO}_3)_x(\mathrm{OH})_2$  seems preferable over substitution for  $\mathrm{SO}_4^{2-}$ . In the spectra of the samples it was possible to observe the peaks corresponding to the  $\mathrm{CO}_3^{2-}$  groups at 874, 1418 and 1482 cm<sup>-1</sup> (Figure 2). The decomposition of carbonate-containing hydroxylapatite at T > 700 °C leads to the formation of  $\mathrm{Ca}_3(\mathrm{PO}_4)_2$ . Only one very week peak of  $\mathrm{SiO}_4^{2-}$  groups at 890 cm<sup>-1</sup> could be detected at Si–HA samples. The silicon content of the samples prepared by reaction (3) did not exceed 2 wt.% according to quantitative X-ray fluorescence analysis.

The TEM micrographs of as-precipitated powders of HA and Si-HA are shown in Figure 3, where submicron-sized particles can be observed. Note that silicon doping switches the crystal shape from uniaxial to elongated. The excess of silicon was presented in the form of a separate amorphous SiO<sub>2</sub>·yH<sub>2</sub>O phase.

The bioactivity of thermally stable Si–HA ceramics was evaluated *in vitro* in the media of simulated body fluids (SBF): (pH 7.4; Tris buffer) 142 mM Na<sup>+</sup>, 5 mM K<sup>+</sup>, 1.5 mM Mg<sup>2+</sup>, 2.5 mM Ca<sup>2+</sup>, 147.8 mM Cl<sup>-</sup>, 27 mM HCO<sub>3</sub><sup>-</sup>, 1 mM HPO<sub>4</sub><sup>2-</sup>, SO<sub>4</sub><sup>2-</sup>; at 37 °C. The surface of the samples immersed in SBF for 1–10 days were examined with SEM. The formation of the new apatite layer (thickness of about 1 μm after 7 days) on the surface of ceramic pellets was evidenced. Moreover, higher dissolution of Si–HA powders in comparison with pure HA was observed during the experiments in buffered solutions at pH 4.5.




Figure 2 IR spectra of as-precipitated Si-HA samples.




Figure 3 TEM micrographs of HA and Si-HA samples.

The increasing dissolution can be related to intrinsic microstrains of HA crystals due to significant difference in the effective ionic radii of  $PO_4^{3-}$  and  $SiO_4^{4-}$  groups. The accommodation of the lattice to the induced strains can be implemented *via* the surface segregation of silicate ions.

This work was supported by the Russian Foundation for Basic Research (grant no. 02-03-33271a) and the programme 'Universities of Russia' (grant no. UR.06.03.006).

## References

- 1 L. L. Hench, J. Am. Ceram. Soc., 1998, 81, 1705.
- 2 S. R. Kim, J. H. Lee, Y. T. Kim, D. H. Riu, S. J. Jung, Y. J. Lee, S. C. Chung and Y. H. Kim, *Biomaterials*, 2003, 24, 1389.
- 3 I. R. Gibson, S. M. Best and W. Bonfield, J. Biomed. Mater. Res., 1999, 44, 422.
- 4 N. Patel, S. M. Best, W. Bonfield, I. R. Gibson, K. A. Hing, E. Damien and P. A. Revell, J. Mater. Sci. Mater. Med., 2002, 13, 1199.
- 5 M. Sayer, A. D. Stratilatov, J. Reid, L. Calderin, M. J. Stott, X. Yin, M. MacKenzie, T. J. N. Smith, J. A. Hendry and S. D. Langstaff, Biomaterials, 2003, 24, 369.
  - 6 B. Lazoryak, V. Golubev and R. Aziev, *Kristallografiya*, 1988, **33**, 1113 (*Crystallography USSR*, 1988, **33**, 659).

Received: 4th June 2004; Com. 04/2300